Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 88 clinical trials
featured
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or

daratumumab
refractory multiple myeloma
  • 71 views
  • 28 May, 2020
  • 28 locations
featured
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High

  • 154 views
  • 25 Mar, 2021
  • 1 location
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 29 Apr, 2021
  • 37 locations
INCB001158 Combined With Subcutaneous (SC) Daratumumab Compared to Daratumumab SC in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or

  • 20 views
  • 03 Feb, 2021
  • 45 locations
Treatment of POEMS Syndrome With Daratumumab

This trial investigates the use of Daratumumab (DARA), an antibody directed at the human cluster of differentiation 38 (CD38) molecule, for the treatment of patients with Polyneuropathy

  • 0 views
  • 07 Mar, 2021
  • 1 location
SELIBORDARA: Selinexor Bortezomib and Daratumumab in Multiple Myeloma

Phase 2, single-arm, open, non-randomized, multicenter study of the SINE compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. 100 mg selinexor

monoclonal antibody therapy
proteasome inhibitor
monoclonal protein
monoclonal antibodies
lenalidomide
  • 16 views
  • 15 Feb, 2021
  • 15 locations
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction Follow by Dara Consolidation

drugs combo did not prove gain against three drugs One of the three drugs protocol studied as induction was CTD scheme (cyclophosphamide+ thalidomide+dexamethasone). Daratumumab has a novel mechanism of

  • 0 views
  • 22 Jan, 2021
  • 1 location
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma

achieved after first-line therapy. Currently, daratumumab (Dara) is approved by the american FDA and EMA in combination with lenalidomide (Len) and dexamethasone (Dex) or bortezomib and Dex for the

remission
proteasome inhibitor
daratumumab
lenalidomide
line of therapy
  • 0 views
  • 23 Jan, 2021
  • 1 location
Daratumumab Pomalidomide and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with daratumumab

vasectomy
measurable disease
proteasome inhibitor
monoclonal antibodies
platelet count
  • 0 views
  • 16 Apr, 2021
  • 10 locations
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

proliferation and survival. Daratumumab is a first-in-class human IgG1 monoclonal antibody (mAb) that binds CD38-expressing malignant cells with high affinity. Daratumumab induces tumor cell death

  • 2 views
  • 24 Jan, 2021
  • 41 locations